Sunitinib-Induced Myositis Detected on 18F-FDG PET/CT.

Suthar, Ritesh R; Purandare, Nilendu; Shah, Sneha; Agrawal, Archi; Puranik, Ameya; Rangarajan, Venkatesh · Clin Nucl Med · 2022

case_report · Level V

Where this comes from

Abstract

Sunitinib is one of the most commonly used multikinase inhibitors for metastatic renal cell carcinoma. Myositis is one of the rarest known adverse effects of sunitinib. Presenting herewith one such case with its relevant imaging findings on FDG PET/CT and ultrasound.

Medical subject headings